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7SECOND ANNUAL INTERNATIONAL UMBILICAL CORD
BLOOD SYMPOSIUM
LOS ANGELES, CALIFORNIA, MAY 14-15, 2004ymposium Summaryhe Symposium faculty consisted of 23 speakers from the United States, Italy, France, Spain, Germany, and
apan. The program was divided into 7 sessions: (I) unrelated donor cord blood transplantation in adults, (II)
ractical aspects of cord blood transplantation, (III) optimal supportive care in cord blood transplantation,
IV) cord blood transplantation for childhood/genetic disorders, (V) immune status after cord blood trans-
lantation, (VI) ex vivo expansion and regenerative medicine, and (VII) contemporary issues in cord blood
anking. Program details are listed at http://cordbloodsymposium.org/home2004.html. The following com-
ents emphasize signiﬁcant aspects of selected presentations. Further details are provided in the abstracts
hat follow.
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vSession I reviewed cord blood transplantation
CBT) in adults.
A large majority of patients in need of a hemato-
oietic cell transplant are adults, and a signiﬁcant
ody of data is accumulating regarding the effective-
ess of cord blood for this population. This is a most
ritical issue regarding the ability of cord blood units
o fulﬁll society’s need for a source of stem cell prod-
cts for all patients requiring a transplant.
Dr. Pablo Rubinstein reviewed data from the Na-
ional Cord Blood Program of the New York Blood
enter on transplantation of 391 (92.9%) of 421
dults who underwent transplantation with cord blood
nits since 1995. Thus, these data include transplan-
ations performed early in the history of CBT. More
han 90% had leukemia (41% advanced), lymphoma,
r myelodysplasia. Factors contributing to a favorable
utcome were a cell dose of2.5 107/kg, total body
rradiation (TBI) conditioning, and HLA match.
verall survival was 30.2% at 1 year and 23% at 5
ears after transplantation. Patients with good HLA
atches (6/6 or 5/6 without rejection mismatches)
nd those conditioned with TBI and ﬂudarabine
FLU) had 68% survival at 1 year. He concluded that
emarkable improvement in the overall survival rate of
dults who undergo transplantation with cord blood is
ossible by improvements in HLA matching and con-
itioning regimens.
Dr. John Wagner discussed novel approaches to
mproving engraftment of cord blood units. This in-
he publication of the abstracts and the summary of the 2004 Interna-
ional Umbilical Cord Blood Transplantation Symposium is supported bysn educational grant from StemCyte International Cord Blood Center.
28luded approaches such as double unit transplantation,
x vivo expansion, and co-infusion of mesenchymal
tem cells. He presented data on 23 adult and adoles-
ent patients (median age, 24 years; range, 13-53
ears) with high-risk hematologic malignancy who
nderwent transplantation with 2 partially HLA-
atched umbilical cord blood (UCB) units after my-
loablative conditioning. The median total infused
ell dose was 3.5  107 nucleated cells (NCs) per
ilogram (range, 1.1-6.3). All evaluable patients (n 
1) engrafted at a median of 23 days (range, 15-41
ays), with 1 unit predominating. Although there was
o association between NC dose, CD34 cell dose, or
LA-A, -B, or -DRB1 match and which unit predom-
nated, the winning unit had a higher CD3 dose. The
ncidence of severe grade III to IV acute graft-versus-
ost disease (GVHD) was 13% (95% conﬁdence in-
erval [CI], 0%-26%), and disease-free survival (DFS)
as 57% (95% CI, 35%-79%) at 1 year. These sug-
est that (1) double unit UCBT is safe, with 1 unit
redominating over time; (2) the unit that disappears
ver time may facilitate engraftment of the winning
nit, possibly by immune-mediated mechanisms; and
3) CD3 dose might predict which unit will ultimately
ngraft long-term. Most importantly, the use of 2
CB units extends the application of this treatment to
early all adults for whom 1 unit would have been
nsufﬁcient.
Dr. Juliet Barker discussed UCB transplantation
UCBT) after nonmyeloablative conditioning in high-
isk adults. Fifty-one adults with advanced hemato-
ogic malignancies (median age, 50 years; range, 19-
0), ineligible for myeloablative conditioning by
irtue of advanced age, extensive prior therapy, or
erious comorbidities, received UCBT after cyclo-
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Bhosphamide 50 mg/kg, FLU 200 mg/m2, and 200
Gy TBI. Immunosuppression was with cyclosporin A
o at least day 100 and mycophenolate mofetil to day
0. Eight patients with no combination chemotherapy
n the 6 months before transplantation also received
ntithymocyte globulin during conditioning. Thirteen
atients (25%) received single UCB units, and 38
75%) received double unit grafts. The median total
nfused cell dose was 3.4  107 NCs per kilogram
range, 1.1-5.7). Units were predominantly 1- or 2-an-
igen mismatched with the recipient. Fifty patients
ere evaluable, and neutrophil recovery to 0.5 
09/L occurred at a median of 8 days (range, 5-32
ays) in 45. Four patients had failure of donor engraft-
ent with autologous recovery, and 1 had late graft
ejection. The cumulative incidence of sustained do-
or engraftment was 90% (95% CI, 82%-98%), with
median chimerism of 100% (range, 72%-100%) by
ay 100. The cumulative incidences of grade II to IV
nd grade III to IV acute GVHD were 61% (95% CI,
4%-78%) and 27% (95% CI, 14%-40%), respec-
ively, at day 100, and that of chronic GVHD was
6% (95% CI, 20%-52%) at 1 year. The incidence of
ransplant-related mortality (TRM) was 18% (95%
I, 8%-28%) at day 180, and that of relapse/progres-
ive disease was 31% (95% CI, 17%-45%) at 1 year.
egression of relapsed or persistent disease has been
een in patients with myelodysplasia and intermedi-
te- and low-grade lymphoid malignancies (n  8).
he probability of overall and progression-free sur-
ival was 57% (95% CI, 40%-73%) and 48% (95%
I, 32%-63%), respectively, at 1 year. Notably, day
80 TRM in patients aged 45 years was 11% (95%
I, 1%-21%), and in patients with extensive prior
herapy it was 25% (95% CI, 6%-44%). However,
atients with serious pretransplantation comorbidities
ad a high TRM of 45% (95% CI, 20%-70%) at day
80 (P  .01). These data show that this regimen is
oth nonmyeloablative and associated with a high
ncidence of donor engraftment. Further, this ap-
roach extends access to transplantation to many
dults who would otherwise be ineligible on the basis
f a lack of donor or an inability to tolerate high-dose
onditioning.
Dr. Satoshi Takahashi discussed clinical results in
CB recipients with hematologic malignancies with
yeloablative regimens. Sixty-eight adult patients
ith hematologic malignancies received unrelated
BTs, and results were compared with bone marrow
ransplantation (BMT; n  45) from unrelated do-
ors. Some critical results were that neutrophil and
latelet recoveries were slow in CBT compared with
MT and that the probability of grade III and IV
cute GVHD was signiﬁcantly lower than among
MT recipients. There were no GVHD-related
eaths among CBT recipients, compared with 10
eaths out of 24 among BMT recipients, but there was o
B&MTo signiﬁcant difference between CBT and BMT re-
ipients in chronic GVHD incidence. Unrelated CBT
howed better TRM, relapse, and DFS results com-
ared with BMT. The conclusion was that the data
trongly suggest that CBT could be safely and effec-
ively used for adult patients with hematologic malig-
ancies.
Dr. Eliane Gluckman reported a comparison of
nrelated cord blood and BMTs in adults with acute
eukemia. Ninety-eight adults with acute leukemia
iven an HLA-incompatible unrelated cord blood
ransplant (UCBT) were compared with 584 patients
ho had HLA-matched unrelated BMTs performed
etween 1998 to 2002 and reported to Eurocord and
uropean Blood and Marrow Transplant Registry.
ecipients of UCBT were younger (median, 24.5 ver-
us 32 years; P  .001), weighed less (median, 58
ersus 68 kg; P  .001), and had more advanced
isease at transplantation (52% versus 33%; P .001).
ultivariate analysis demonstrated lower risks of
rade II to IV acute GVHD (P  .001) after UCBT;
owever, neutrophil recovery was signiﬁcantly de-
ayed (P  .001). TRM, relapse, chronic GVHD, and
eukemia-free survival were comparable between
CBT and unrelated BMT recipients.
Dr. Guillermo F. Sanz described the results of
nrelated-donor CBT in 20 adult patients with
hronic myeloid leukemia. Fourteen were in chronic
hase (CP; 8 in CP1 and 6 in CP2), 2 in accelerated
hase, and 4 in blast crisis. With a median follow-up
f 49 months (range, 28-82 months), the probability
f DFS at 3 years was 40% and was related to age (P
.01) and the phase of the disease at transplantation
P  .04). The probability of DFS at 3 years was 60%
or patients younger than 31 years and 57% for those
ho underwent transplantation in CP. Six of 8 pa-
ients aged 30 years or younger who underwent trans-
lantation in CP remain alive and disease free. The
onclusion reached was that unrelated-donor CBT is
n acceptable alternative for younger patients with
hronic myeloid leukemia in CP who require trans-
lantation and lack an HLA-matched family or unre-
ated bone marrow donor.
Dr. Mary Laughlin reported that UCBs are in-
reasingly used in older subjects. She reported a com-
arison of the results of 169 1-antigen mismatched
CBTs and 83 1-antigen mismatched and 367
atched BMTs in patients aged 16 to 60 years with
cute and chronic leukemia.
Rates of treatment-related mortality, treatment
ailure, and overall mortality were similar after mis-
atched BMTs and UCBTs. Although outcomes
ere better after matched transplantations, in a cohort
n which 69% of the patients who had UCBTs were
ismatched at 2 loci and had advanced leukemia at
ransplantation, outcomes were comparable to those
bserved after 1-antigen-mismatched BMT. The con-
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7lusion reached was that use of UCB units mis-
atched at 2 loci will increase donor availability for
lder subjects.
Session II reviewed the factors important in
he selection of the optimal CBU for transplanta-
ion.
Dr. Efﬁe Petersdorf described a new model for
ptimal HLA matching of unrelated donors in which
uantitative and qualitative measures of donor/recip-
ent disparity are considered and in which stage of
isease at the time of transplantation may inﬂuence
he effect of HLA disparity. Routine testing of pro-
pective patients and their best-matched donors
hould include high-resolution DNA typing for
LA-A, -B, -C, -DRB1, and -DQB1. If a fully
atched donor is not available, then mismatching
hould be limited to 1 or 2 loci, with preference to
llele-level rather than antigen-level mismatches.
Dr. Lee Ann Baxter-Lowe pointed out that for the
ord blood units currently searched by the National
arrow Donor Program, at least one 4/6 HLA-
atched cord blood unit with at least 80  107 TNC
s available for nearly all patients. Although HLA
atching improves outcomes, CBTs can be successful
ith only 3/6 or 4/6 HLA matches. For BMT, HLA
isparity detected by performing high-resolution
LA typing and typing of additional HLA loci has
een associated with adverse outcomes, and it is hy-
othesized that these observations are likely to be
pplicable to CBT. This hypothesis is being tested by
he National Institutes of Health COBLT study,
hich has reported an interim analysis of high-reso-
ution typing of 188 donor/recipient pairs, the clinical
igniﬁcance of which is under investigation. Until the
elationship between HLA matching and transplanta-
ion outcomes is well understood, high-resolution
yping might be considered for selection of cord blood
nits for transplantation.
Dr. Juliet Barker discussed issues in the selection
nd availability of UCB versus volunteer donor bone
arrow. She highlighted that although major efforts
ave been made to increase minority representation
nd speed search times of volunteer donors, many
atients in need of urgent transplantation are not able
o identify a suitable donor in a timely fashion. In
ddition, efforts to match donor/recipient pairs at the
LA-A, -B, -C, and -DRB1 alleles may further limit
he donor pool and potentially prolong searches. In
ontrast, UCB has the major advantage of tolerance of
imited HLA disparity and rapid availability. At the
niversity of Minnesota, the median time to obtain a
CB graft was 13.5 days, as compared with 50 days
or a volunteer bone marrow donor. Clearly, low cell
ose is a major limitation of UCBT for adults and
arger adolescents. However, strategies such as double
nit transplantation and ex vivo expansion may be able
o address this problem. For example, of 122 consec- y
30tive adult transplant referrals who had a formal UCB
earch, by using UCB unit-selection criteria of 4/6 to
/6 HLA-A, -B, and -DRB1 match and combining 2
nits for patients with no single unit 3.5  107 NCs
er kilogram, a satisfactory graft was identiﬁed for all
atients. A further issue is that UCB searches are not
entralized and that banking standards can vary, which
an sometimes give rise to concerns about unit quality.
verall, because there have been no randomized trials
f volunteer donor BMT versus UCBT, how these 2
tem cell sources compare is not known. Currently,
he choice of stem cell source is based on diagnosis,
egree of urgency, relative availability of adequately
atched bone marrow versus UCB of adequate match
nd dose, institutional research priority, and physician
reference.
Session III consisted of a panel discussion re-
arding the optimal supportive care in CBT.
Dr. Richard Champlin was the moderator, and top-
cs discussed included the optimal preparative regi-
en, requirements for engraftment, the role of non-
yeloablative regimens, the role of antithymocyte
lobulin, optimal GVHD prophylaxis, growth factors,
nfection prophylaxis, long-term follow-up, and pa-
ient selection.
Session IV reviewed CBT for childhood/ge-
etic disorders.
Dr. Joanne Kurtzberg indicated that unrelated do-
or UCB has been used for transplantation in 100
nfants and children with inborn errors of metabolism
n her medical center since 1995. Cord blood cells
xhibit immunologic tolerance, allowing transplanta-
ion across partially mismatched HLA barriers and
ncreasing access to allogeneic transplantation therapy
or patients in need, and may also be capable of trans-
ifferentiation into nonhematopoietic tissues.
All children were prepared for transplantation
ith myeloablative chemotherapy consisting of busul-
an, cyclophosphamide, and antithymocyte globulin.
rophylaxis against GVHD was administered with
yclosporine and methylprednisolone. Thirty-ﬁve
oung children with Hurler syndrome, all with the
evere phenotype (MPS I), underwent transplantation
ith partially HLA-mismatched unrelated donor
CB over the past 8 years. Moderate to severe acute
VHD occurred in 28% of patients. Extensive
hronic GVHD was not seen. Twelve percent of pa-
ients had serious events: graft rejection (n  1), in-
ectious deaths (n  3), or toxic death (n  1; hyper-
mmonemia). All other patients (87%) are surviving
vent free for a median 3 years.
Additional children (n  60) with lysosomal
torage diseases—including metachromatic leukodys-
rophy, adrenoleukodystrophy, and globoid leuko-
ystrophy (Krabbe disease)—have undergone trans-
lantation with unrelated donor UCB over the past 9
ears. In asymptomatic children, disease was arrested
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Before the onset of neurologic dysfunction. In symp-
omatic children, disease progression was arrested
ithin 6 to 9 months of the transplantation. In a child
ith advanced Krabbe disease who died 1 year after
ransplantation, engraftment of donor cells was noted
n the brain. Differentiation to oligodendrocytes was
emonstrated in vitro and subsequently in vivo. In a
hild with MPS III (Sanﬁlippo syndrome), donor cells
ifferentiated into cardiac myocytes in the heart 6
onths after transplantation.
Dr. Marco Zecca discussed unrelated donor CBT
or children with hematologic malignancies. The ex-
erience derived from transplantations in hundreds of
hildren with acute lymphoblastic or myeloid leuke-
ia indicates that the results achieved are substantially
omparable to those obtained in children given
MTs. In particular, the risk of leukemia recurrence is
ot increased after CBT, suggesting a graft-versus-
eukemia effect as with BMT. Disease status at the
ime of transplantation is the main factor inﬂuencing
atients’ outcome; patients who undergo transplanta-
ion in the ﬁrst or second remission are those with the
est results. Because most deaths in children given
BT are due to infectious complications (related to
oth delayed hematopoietic recovery and lack of
doptive transfer of memory T cells), strategies able to
ccelerate both hematopoietic and immune reconsti-
ution could widen the use of cord blood cells for
ransplantation.
Dr. Mark Walters discussed the role of CBT in
halassemia and pointed out that 1500 patients with
halassemia have received a hematopoietic cell trans-
lant. The alternative of increasingly effective sup-
ortive care also affects the decision to pursue trans-
lantation. Initial results of UCBT for thalassemia
largely with sibling donors) suggest that acceptable
utcomes are possible if measures are taken to miti-
ate the risk of graft rejection. Among 44 patients with
ickle cell disease or thalassemia who received aug-
ented conditioning therapy, the event-free survival
as 94%, compared to 62% among those who re-
eived a standard combination of busulfan and cyclo-
hosphamide, with or without horse antithymocyte
lobulin. The clinical experience with unrelated
CBT for thalassemia remains very limited. New
echniques to prevent GVHD and promote engraft-
ent, coupled with reﬁned donor selection criteria,
hould expand the availability of transplantation for
halassemia major.
Dr. Eliane Gluckman reported results of 44 patients
ith Fanconi anemia who received an unrelated CBT
UCBT). The median age was 7.7 years, and median
ollow-up was 20 months (range, 8-83 months). At
CBT, the median number of neutrophils was 620/
L, and 13 patients had received more than 20 red
lood cell transfusions. The cord blood was HLA
ismatched in 37 patients. The median number of t
B&MTCs at freezing was 5.5  107/kg and at infusion was
.7  107/kg. Eighteen patients received cyclophos-
hamide and irradiation–based preparative regimens,
2 patients received FLU-containing regimens, 6 re-
eived cyclophosphamide alone, and 8 received other
egimens. GVHD prophylaxis consisted of cyclo-
porin A and methotrexate (43%) or cyclosporin A
lone (23%). Neutrophil recovery at day 60 was
6%  8%; cell dose and number of HLA disparities
ere associated with a higher probability of neutrophil
ecovery. Acute GVHD (grade II-IV) was 23%  6%
grade II, 7%; grade III, 7%; grade IV, 11%), and
hronic GVHD occurred in 4 (19%) of 21 patients at
isk. Two-year survival was 36%  7%. In multivar-
ate analysis, 2 factors were associated with better
urvival: NC at freezing (5.5  107/kg; hazard ratio,
.25; P  .004) and FLU-containing preparative reg-
men (hazard ratio, 0.16; P  .018). In patients receiv-
ng a higher cell dose, 2-year survival was 55%, versus
6% for those receiving a lower dose (P .005); it was
7% for those receiving a FLU-containing regimen
ompared with 25% (P  .016) for those receiving
ther regimens. The conclusion reached was that re-
ults of UCBT for Fanconi anemia patients are ac-
eptable and can be improved by better selection of
he cord blood units and by use of FLU in the pre-
arative regimen.
Session V reviewed immune status after CBT.
Dr. Bruce Blazar reviewed the role of
D4CD25 T-regulatory cells in allogeneic BMT.
subpopulation of CD4 T cells that coexpresses
D25, the interleukin-2 receptor  chain, without
vidence of prior activation, has been shown to be
mportant in self-tolerance by suppressing autoim-
une responses. The authors’ extensive preclinical
tudies demonstrated that depletion of either host
D25 cells before BMT or donor CD25 cells in
he donor graft inoculum markedly accelerated
VHD lethality. In contrast, supplementing the do-
or graft with fresh CD4CD25 T-regulatory cells
elayed GVHD lethality, and adding ex vivo–activated
nd expanded T-regulatory cells virtually abolished
VHD lethality. Their experiments led them to con-
lude that the infusion of ex vivo–activated and ex-
anded CD4CD25 cells is a highly potent means of
nhibiting GVHD and facilitating alloengraftment,
nd they suggest that a clinical trial of CD425
erits consideration in the context of allogeneic
MT.
Dr. Kenneth Weinberg pointed out that immune
econstitution after hematopoietic stem cell (HSC)
ransplantation is a fundamental problem that affects
he clinical outcome of transplantation, regardless of
he stem cell source. Some of the features of UCBC
hat make them attractive as a source of HSCs may
lso contribute to difﬁculties in immune reconstitu-
ion. Although the number of HSCs in UCBC sources
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7ay be limiting, the increased proliferative potential
f cord blood HSCs could also be advantageous. A
ajor difference between UCBC and adult marrow or
eripheral blood stem cells is the nature of the mature
lymphocytes: the T lymphocytes in UCBC are
redominantly naive, whereas adults have mainly
emory T lymphocytes. A decreased ability to stim-
late naive T cells may account for reduced alloreac-
ivity in UCBC but may also lead to decreased sensi-
ivity to nominal antigens such as viruses. Naive T
ymphocytes depend on self-antigen and interleukin-7
s signals for homeostatic proliferation. Interleukin-7
herapy is an attractive strategy for promoting post-
ransplantation thymopoiesis but may be complicated
y exacerbation of GVHD. Some approaches for
ranslation of these experimental concepts into empir-
cal studies in UCBC transplantation are being
tudied.
Dr. Juliet Barker shared the results of a review of
erious infectious complications in children who un-
erwent myeloablative unrelated donor transplanta-
ion at the University of Minnesota with unmanipu-
ated bone marrow (n 52), bone marrow with T-cell
epletion (TCD, n  24), or UCB (n  60) between
994 and 2004. Analysis of the relative risk (RR) of
nfection within days 0 to 42, 43 to 100, and 101 to
80 revealed no differences between groups except a
reater risk of viral infections from days 0 to 42 in
CD as compared with bone marrow recipients (RR,
.5; P  .02). After day 180, TCD recipients had the
reatest infection risk (RR, 3.1; P  .03), whereas risk
n UCB (RR, 0.5; P  .23) was comparable to that in
one marrow recipients and superior to TCD. These
ata suggest that although serious infection is a major
roblem for all unrelated donor recipients, regardless
f stem cell source, the risk of serious infection after
ediatric UCBT is comparable to that of unmanipu-
ated bone marrow and superior to TCD.
Session VI reviewed ex vivo expansion and re-
enerative medicine.
Dr. Elizabeth Shpall reported on several trials in-
olving ex vivo expansion of cord blood. In one study,
3 patients with hematologic malignancies (n 40) or
reast cancer (n  3) received high-dose therapy fol-
owed by unrelated allogeneic CBT. A fraction of each
atient’s cord blood allograft was CD34-selected and
ultured ex vivo for 10 or 14 days before transplanta-
ion in deﬁned media with stem cell factor, granulo-
yte colony-stimulating factor, and megakaryocyte
rowth and differentiation factor. The remainder of
he cord blood graft was infused without further ma-
ipulation. This study demonstrated that the CD34
election and ex vivo expansion of cord blood before
ransplantation is feasible. The engraftment failure
ate was relatively low, and the time to neutrophil in
arge adults was in the range reported for pediatric
ecipients of much larger cord blood cell doses. Two A
32dditional trials are in progress at the M. D. Anderson
ancer Center. In these trials, patients with hemato-
ogic malignancies are being randomized to receive
ither 2 unmanipulated cord blood units or 1 unma-
ipulated unit and 1 unit from which all the cells are
xpanded ex vivo. Future directions include the use of
esenchymal stem cells as a supportive stroma for the
xpansion of cord blood mononuclear cell progeni-
ors, developed by McNiece et al.
Dr. Peter Wernet discussed the isolation of non-
SCs from UCB. He pointed out that an intrinsically
luripotent CD45 population from placental cord
lood, termed unrestricted somatic stem cells, grows ad-
erently and can be expanded to large quantities of
ells without losing pluripotency. In vitro one can
emonstrate unrestricted somatic stem cell homoge-
eous differentiation into osteoblasts, chondroblasts,
dipocytes, and hematopoietic and neural cells, in-
luding astrocytes and neurons expressing neuroﬁla-
ent, sodium channel protein, and various neuro-
ransmitter phenotypes. In vivo experiments in animal
odels demonstrate differentiation into cells of vari-
us tissue types after injection into speciﬁc cites. No
alignant transformation was observed in any of the
nimals.
Morey Kraus discussed potential applications of
CB-derived non-HSCs. The potential of such cells
as been studied with encouraging results in a rat
troke recovery model, in SOD1G93A mice in the
tudy of ALS, after myocardial infarction or acute
schemia, and in the Mdx mouse mode of muscular
ystrophy.
Session VII reviewed contemporary issues re-
arding cord blood banking.
Dr. Michael Creer pointed out that cryopreserva-
ion and thawing of cord blood products are the single
reatest and most variable sources of HSC loss from
ollection to infusion. A series of studies examined the
ffects of cooling rate and type of cryoprotectant (di-
ethyl sulfoxide or propanediol) on cord blood HSC
ell number (TNC and CD34), viability (trypan blue
r 7-AAD), and function (colony-forming unit assay)
fter thawing. Varying the cooling rate from 1 to
20°C/min had little effect on recovery of cord blood
SCs or trypan blue viability. However, cord blood
SC function (colony-forming unit recovery) de-
reased markedly at cooling rates above 5°C/min.
ransfer of cord blood units in Styrofoam containers
ith liquid nitrogen or segment removal in liquid
itrogen vapor did not cause any detectable loss of
SC number, viability, or function. Similarly, re-
eated exposure of frozen cord blood units to 10
onsecutive 1-minute intervals at room temperature
lso had no signiﬁcant effect on HSC number, viabil-
ty, or function.
Dr. Ellen Lazarus discussed the Food and Drug
dministration regulatory approach to human cell and
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Bissue products and how this applies to cord blood
nits. She indicated that peripheral blood stem cells
nd cord blood are regulated as biologic cell therapies
nder the tissue approach. Implementation of the reg-
latory approach is under way, and a period of en-
orcement discretion for unrelated donor cord blood t
ematologic malignancy were transplanted with two partially HLA-
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B&MTs ongoing. Cord blood manufacturers currently must
egister with the Food and Drug Administration. Fi-
alizing regulations is currently a Food and Drug
dministration priority. There is a recognized need
or international harmonization of cord blood regula-
ions.ymposium Abstracts1
ORD BLOOD TRANSPLANTATION TO ADULT PATIENTS: A SINGLE-
ANK’S EXPERIENCE
tevens, C.E., Scaradavou, A., Rubinstein, P. National Cord Blood Pro-
ram of the New York Blood Center
Since 1993, the New York Blood Center has provided cord blood
CB) grafts to more than 1500 recipients, 421 of whom where adults
age 16). These patients were treated in 53 US and 26 non-US
ransplant Centers (TCs). Data from 391 (92.9%) are available.
he proportion of adult recipients has grown from 9% in 1995 to
ver 30% in 2001-2003. More than 90% (363/391) had leukemia
41% advanced), lymphoma, or myelodysplasia. No. of patients
ged 16-24, 25-39, and 40: 130, 135, and 125, respectively; there
ere 15% African American recipients, 13.3%Hispanic, and 65.6%
aucasoids, respectively. TNC doses 2.5  107/kg were given to
2%, 25-49  107/kg to 37%, and 5  107/kg to 1.3% of all
ecipients. HLA was matched at serological levels for A and B and
t DNA allele level for HLA-DR. Seven TCs have performed 10
B transplantations each. Neutrophil engraftment was signiﬁcantly
educed when TNC doses2.5 107/kg and stratiﬁed signiﬁcantly
ith HLA mismatch levels. Engraftment was superior with TBI
onditioning compared to no TBI; and regimens including meth-
trexate associated with reduced engraftment. Overall survival was
0.2% at one year and 23% at ﬁve years post-transplant. Centers
ith 10 CB transplantations had better survival (by Cox Regres-
ion analysis) and so did those with better HLA matches, those
ithout advanced stage leukemia, and those whose conditioning
ncluded ﬂudarabine. The effect of cell dose was not signiﬁcant in
he Cox regression. Patients with good HLA matches (6/6 and 5/6
ithout rejection mismatches) and those conditioned with regimens
ncluding TBI and ﬂudarabine had excellent survival: 68% at one
ear, respectively.
The data indicate that, despite the low graft cell doses, remarkable
mprovement in overall survival rate of adults transplanted with
ord blood is possible by improvements in HLA matching and
onditioning regimens.
2
MBILICAL CORD BLOOD TRANSPLANTATION: NOVEL APPROACHES
OWARD IMPROVING ENGRAFTMENT
agner, J.E., Barker, J. Blood and Marrow Transplant Program,
niversity of Minnesota, Minneapolis, MN.
Cryopreserved umbilical cord blood (UCB) has been investigated
s a potential strategy for augmenting the pool of acceptable donors,
educing the risks of acute and chronic graft-versus-host disease
GVHD) and improving survival. Cell dose, however, has clearly
een identiﬁed as a major limitation, often preventing the consid-
ration of UCB for adult recipients. Recipients of 1.7 
05CD34/kg have slow hematopoietic recovery (median 35 days)
nd signiﬁcantly lower incidence of engraftment (68% [95% CI,
6-91]). Therefore, strategies for increasing the cell dose, e.g., ex
ivo HSC expansion, transplantation of multiple UCB units, and
o-infusion of healthy haploidentical mesenchymal stem cells
MSC), are being explored.
Multi-unit UCB transplantation. Twenty-three adult and adoles-
ent patients [median age 24 years (range: 13-53)] with high-riskatched UCB units after myeloablative conditioning. The median
otal infused dose 3.5  107NC/kg (range 1.1-6.3). All evaluable
atients (n  21) engrafted at a median of 23 days (range 15-41)
ith one unit predominating. While there was no association be-
ween nucleated cell dose, CD34 cell dose, or HLA-A,B,DRB1
atch and which unit predominated, the winning unit had a higher
D3 dose. Incidence of severe III-IV acute graft-versus-host
isease (GVHD) was 13% (0-26%), and disease-free survival was
7% (95% CI: 35-79) at 1 year. These data suggest that 1) double
nit UCBT is safe with one unit predominating over time, 2) the
nit that disappears over time may facilitate engraftment of the
inning unit, possibly by immune mediated mechanisms, and 3)
D3 dose might predict which unit will ultimately engraft long
erm. Most importantly, the use of two UCB units extends the
pplication of this treatment to nearly all adults for whom one unit
ould have been insufﬁcient.
Co-Infusion of haploidentical MSC and UCB transplantation. Fifteen
atients [median age 7.5 years (range: 0.2-16)] with high risk leu-
emia were transplanted with HLA 0-2 antigen mismatched UCB
nd haploidentical parental donor MSC after a myeloablative con-
itioning. No toxicity was observed related to the infusion of MSC.
ll treated patients (n  8) had hematopoietic recovery and com-
lete chimerism at a median of 19 days (range: 9-28). Platelet
ecovery occurred at a median of 1.7 months (range: 1.2-3.3).
ncidence of grade II-IV acute GVHD was 2 of 8 patients with no
atient having chronic disease. With a median followup of 2.9 years,
patients are alive and disease free with two patients dying of
nfections on days 53 and 63, respectively. These data suggest that
ngraftment, particularly platelet recovery, may be enhanced by the
o-infusion of MSC. Clearly larger patient numbers are required to
onﬁrm these preliminary observations.
3
MBILICAL CORD BLOOD TRANSPLANTATION AFTER A NON-MYELOA-
LATIVE THERAPY IN HIGH RISK ADULTS
agner, J.E., Barker, J. Blood and Marrow Transplant Program,
niversity of Minnesota, Minneapolis, MN.
Bone marrow transplantation (BMT) in adults is associated with a
igh risk of graft-versus-host disease (GVHD), opportunistic infec-
ion and regimen related toxicity. For these reasons, umbilical cord
lood (UCB) after a non myeloablative preparative regimen has
een explored.
Fifty-one adults with advanced hematologic malignancies [median
ge 50 years (range 19-60)], ineligible for myeloablative condition-
ng by virtue of advanced age, extensive prior therapy or serious
o-morbidities received UCB transplantation after cyclophospha-
ide 50 mg/kg, ﬂudarabine 200 mg/m2, and 200 cGy TBI. Immu-
osuppression was with cyclosporine-A to at least day 100 and
ycophenolate mofetil to day 30. Eight patients with no combina-
ion chemotherapy in the 6 months prior to transplant also received
TG during conditioning. Thirteen patients (25%) received single
CB units and 38 (75%) received double unit grafts. The median
otal infused cell dose was 3.4  107NC/kg (range 1.1-5.7). Units
ere predominantly 1-2 antigen HLA mismatched with the recip-
ent. Of 50 evaluable patients, neutrophil recovery occurred at a
edian of 8 days (range 5-32). Four patients had failure of donor
erived engraftment with autologous recovery and 1 had late graft
ejection. The cumulative incidence of sustained donor engraftment
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